ArticleJournal of thoracic disease2026
Quantitative assessment of risk stratification of acute pulmonary embolism based on three-dimensional computed tomography bronchography and angiography.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnosing lung cancer invading the pulmonary artery using ultra-low-dose CT pulmonary angiography: a feasibility study.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate assessment and severity grading of acute pulmonary embolism (APE) currently relies on the Simplified Pulmonary Embolism Severity Index (sPESI) combined with biomarkers or right ventricular function indicators in clinical practice, which increases implementation complexity. Computed tomography pulmonary angiography (CTPA) remains the preferred imaging modality for confirming APE, while the commonly used Qanadli semi-quantitative scoring system has limited accuracy. This study aimed to explore the feasibility of quantitatively assessing risk stratification in patients with APE using three-dimensional computed tomography bronchography and angiography (3D-CTBA). Methods: Sixty-one patients with APE who underwent CTPA at the First Affiliated Hospital of Hebei North University were retrospectively enrolled. Clinical data were collected, and 3D-CTBA was performed using Mimics software to reconstruct pulmonary artery and embolism models. The thrombus volume-to-pulmonary artery volume ratio was calculated. Spearman correlation analysis was used to evaluate associations between this ratio, the computed tomography pulmonary artery obstruction index (Qanadli score), and related parameters, including the right ventricle-to-left ventricle (RV/LV) ratio and laboratory biomarkers. Receiver operating characteristic (ROC) curves were constructed, and the area under the curve (AUC) was calculated to assess the predictive efficacy of the thrombus volume-to-pulmonary artery volume ratio for risk stratification. Results: A strong correlation was observed between the thrombus volume-to-pulmonary artery volume ratio and the Qanadli score (r=0.732, P<0.001). The ratio showed moderate correlations with RV/LV (r=0.448, P<0.001), B-type natriuretic peptide (BNP; r=0.566, P<0.001), and creatinine kinase-myocardial band (CK-MB; r=0.495, P<0.001), and a weak correlation with D-dimer (r=0.371, P=0.003). In contrast, the Qanadli score correlated weakly with RV/LV (r=0.381, P=0.002) and moderately with BNP (r=0.439, P<0.001) and CK-MB (r=0.467, P<0.001), but showed no correlation with D-dimer (r=0.136, P=0.30). In ROC curve analysis, the AUC for the thrombus volume-to-pulmonary artery volume ratio was 0.847, compared with 0.811 for the Qanadli score (Z=0.629, P=0.53). Conclusions: The thrombus volume-to-pulmonary artery volume ratio derived from 3D-CTBA provides a reliable quantitative method for risk stratification in patients with APE. This approach may serve as a complementary or alternative tool to the Qanadli score in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.